Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Helen Heslop, M.D.

Helen E. Heslop, M.D.

 

Helen E. Heslop, M.D.

Helen E. Heslop, M.D.

Senior Affiliate Member
The Methodist Hospital Research Institute
Director, Adult Stem Cell Transplantation Program,
Center for Cell and Gene Therapy
Dan L. Duncan Chair
Professor of Pediatrics and Medicine, Section of Hematology/Oncology
Baylor College of Medicine

Phone: 832-824-4662
Fax: 832-825-4668
E-mail: hheslop@bcm.tmc.edu

Education

M.B.   University of Otago, Dunedin, New Zealand (Medicine)
FRACP   Royal Australasian College of Physicians, Sydney, Australia (Medicine)
FRCPA   Royal College of Pathologists of Australasia, Sydney, Australia (Hematology)
M.D.   University of Otago Medical School, Dunedin, New Zealand (Immunology)

Postdoctoral Training

Research Fellowship, Royal Free Hospital, London, England
Postdoctoral Research Fellowship, St. Jude Children's Research Hospital, Memphis, TN

 

Biography

Dr. Heslop's initial faculty appointment was as Assistant Member of the Division of Bone Marrow Transplantation in the Department of Hematology-Oncology at the St. Jude Children's Research Hospital, in Memphis in 199. She was promoted to Associate Member in 1994. She also held an appointment as Associate Professor in the Department of Pediatrics at the University of Tennessee in Memphis. Dr. Heslop received her current appointments at the Baylor College of Medicine in Houston, Texas in 1997. She was named as the first Dan L. Duncan Chair for Baylor College of Medicine in 2006.

Description of Research

Dr. Heslop's research centers on adoptive immunotherapy with gene-modified effector cells to improve hemopoietic stem cell transplantation and cancer therapy. She currently directs a Lymphoma SPORE program and a program project grant from the NCI, as well as a Specialized Center of Research from the Leukemia and Lymphoma Society. Her research focus is to develop safe and effective T-cell immunotherapies for lymphoma and other Epstein-Barr virus-associated malignancies, including Hodgkin's Disease and nasopharyngeal cancer. Dr. Heslop also runs studies using third party CTLs to treat viral infections after transplant.

Major Areas of Research

Cancer, adoptive immunotherapy, effector cells, hemopoietic stem cell transplantation

Recent Publications

Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. (Plenary paper)  Blood. 2010;115:925-935

Ahmed N, Salsman VS, Kew Y, Shaffer D,  Powell S, Leung HE, Wels W7,  Grossmann R, Heslop HE, Gottschalk SM HER2-specific T cells target primary Glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 ;16:474-85

Melenhorst JJ, Leen AM, Bollard CM, Proce J, Quigley MQ, Brenner MK, Rooney CM, Barrett AJ, Heslop HE. Allogeneic Virus-Specific T cells with HLA Alloreactivity do not Produce GVHD in Human Subjects  Blood [epub ahead of print]

Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114:4002-4008

Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP,  Yvon E, Weiss HL,  Liu H, Rooney CM, Heslop HE, Brenner MK. The Function of Virus-specific T cells Engineered to Co-Express Tumor-Specific Receptors in Patients with Cancer Nature Medicine. 2008 Nov;14:1264-70.